RORC and non-small cell lung carcinoma: This discrepancy between the clinical outcomes following m-TOR inhibitor treatment and our data showing that NSCLC cells are more sensitive to m-TOR inhibitors compared with MEK inhibitors, may be explained by signalling though feedback loops and parallel signal transduction pathways (Al-Lazikani et al, 2012).